Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-JL1 monoclonal antibody-saporin conjugate
- Development stage
- Preclinical
- Lead developer
- Seoul National University
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-JL1 monoclonal antibody-saporin conjugate is an experimental immunotoxin (antibody-drug conjugate) being investigated for the treatment of acute leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The drug consists of the JL1 monoclonal antibody, which targets a specific developmentally regulated epitope of CD43 (sialophorin) expressed on leukemia blasts across T, B, and myeloid lineages, but absent on normal peripheral blood cells and hematopoietic stem cells. This antibody is conjugated to saporin, a type I ribosome-inactivating protein (RIP) derived from Saponaria officinalis. Upon binding to the target cell and subsequent internalization, saporin catalyzes the depurination of the sarcin/ricin loop of the 28S ribosomal RNA, leading to the irreversible inhibition of protein synthesis and induction of apoptosis. The conjugate has demonstrated potent, dose-dependent anti-leukemic activity in vitro and in preclinical models.
- Other names
- anti-JL1 immunotoxinanti-JL-1 immunotoxinanti-JL 1 immunotoxin
02
Targets
CD43 (CD43 antigen)28S rRNA (28S ribosomal RNA)
Beyond the preview
Go deeper on anti-JL1 monoclonal antibody-saporin conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-JL1 monoclonal antibody-saporin conjugate.